https://www.selleckchem.com/pr....oducts/pf-06650833.h
Major depressive disorder is a common, recurrent illness. Recent studies have implicated the NMDA receptor in the pathophysiology of major depressive disorder. (R,S)-ketamine, an NMDA receptor antagonist, is an effective antidepressant but has numerous side effects. Here, we characterized a novel NMDA receptor antagonist, fluoroethylnormemantine (FENM), to determine its effectiveness as a prophylactic and/or antidepressant against stress-induced maladaptive behavior. Saline, memantine (10 mg/kg), (R,S)-ketamine (30 mg/kg), or FENM (
Like
Comment
Share
